Bone effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitus

Postgraduate Medicine

Volumn 129, Issue 1, 2017, Pages 159-168

  Blevins, Thomas C ^a   Farooki, Azeez ^b  

^a Texas Diabetes and Endocrinology   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Bone mineral density; bone mineral metabolism; bone turnover markers; canagliflozin; fractures; type 2 diabetes mellitus

Indexed keywords

BIOLOGICAL MARKER; CALCIUM; CANAGLIFLOZIN; DAPAGLIFLOZIN; EMPAGLIFLOZIN; MAGNESIUM; OSTEOCALCIN; PHOSPHATE; PLACEBO; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL; SODIUM GLUCOSE COTRANSPORTER 2;

BONE; BONE DENSITY; BONE TURNOVER; CARDIOVASCULAR DISEASE; COMPUTER ASSISTED TOMOGRAPHY; DRUG MECHANISM; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMORAL NECK; FOREARM; FRACTURE; HIGH RISK PATIENT; HUMAN; HYPERCALCIURIA; HYPEROSTOSIS; LUMBAR SPINE; NON INSULIN DEPENDENT DIABETES MELLITUS; OSTEOLYSIS; REVIEW; SEVERE RENAL IMPAIRMENT; WEIGHT REDUCTION; BLOOD; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; FEMALE; GLUCOSE BLOOD LEVEL; MALE; OSTEOPOROSIS;

BIOMARKERS; BLOOD GLUCOSE; BONE DENSITY; CANAGLIFLOZIN; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; OSTEOPOROSIS; SODIUM-GLUCOSE TRANSPORTER 2;

EID: 84999873177     PISSN: 00325481     EISSN: 19419260     Source Type: Journal    
DOI: 10.1080/00325481.2017.1256747     Document Type: Review

References (96)

1. Shanbhogue VV, Mitchell DM, Rosen CJ, et al. Type 2 diabetes and the skeleton:new insights into sweet bones. Lancet Diabetes Endocrinol. 2016;4:159–173.
2. Sellmeyer DE, Civitelli R, Hofbauer LC, et al. Skeletal metabolism, fracture risk, and fracture outcomes in type 1 and type 2 diabetes. Diabetes. 2016;65:1757–1766.
3. Leali PT, Muresu F, Melis A, et al. Skeletal fragility definition. Clin Cases Miner Bone Metab. 2011;8:11–13.
4. Leslie WD, Rubin MR, Schwartz AV, et al. Type 2 diabetes and bone. J Bone Miner Res. 2012;27:2231–2237.
5. Kachroo S, Kawabata H, Colilla S, et al. Association between hypoglycemia and fall-related events in type 2 diabetes mellitus:analysis of a U.S. commercial database. J Manag Care Spec Pharm. 2015;21:243–253.
6. Malabu UH, Vangaveti VN, Kennedy RL., Disease burden evaluation of fall-related events in the elderly due to hypoglycemia and other diabetic complications:a clinical review. Clin Epidemiol. 2014;6:287–294.
7. Napoli N, Strotmeyer ES, Ensrud KE, et al. Fracture risk in diabetic elderly men:the MrOS study. Diabetologia. 2014;57:2057–2065.
8. Saito M, Kida Y, Kato S, et al. Diabetes, collagen, and bone quality. Curr Osteoporos Rep. 2014;12:181–188.
9. Shiraki M, Kuroda T, Tanaka S, et al. Nonenzymatic collagen cross-links induced by glycoxidation (pentosidine) predicts vertebral fractures. J Bone Miner Metab. 2008;26:93–100.
10. Schwartz AV, Garnero P, Hillier TA, et al. Pentosidine and increased fracture risk in older adults with type 2 diabetes. J Clin Endocrinol Metab. 2009;94:2380–2386.
11. Yamamoto M, Yamaguchi T, Yamauchi M, et al. Low serum level of the endogenous secretory receptor for advanced glycation end products (esRAGE) is a risk factor for prevalent vertebral fractures independent of bone mineral density in patients with type 2 diabetes. Diabetes Care. 2009;32:2263–2268.
12. Farlay D, Armas LA, Gineyts E, et al. Nonenzymatic glycation and degree of mineralization are higher in bone from fractured patients with type 1 diabetes mellitus. J Bone Miner Res. 2016;31:190–195.
13. Meier C, Schwartz AV, Egger A, et al. Effects of diabetes drugs on the skeleton. Bone. 2016;82:93–100.
14. Zhu ZN, Jiang YF, Ding T. Risk of fracture with thiazolidinediones:an updated meta-analysis of randomized clinical trials. Bone. 2014;68:115–123.
15. Lecka-Czernik B. Bone loss in diabetes:use of antidiabetic thiazolidinediones and secondary osteoporosis. Curr Osteoporos Rep. 2010;8:178–184.
16. Billington EO, Grey A, Bolland MJ. The effect of thiazolidinediones on bone mineral density and bone turnover:systematic review and meta-analysis. Diabetologia. 2015;58:2238–2246.
17. Benvenuti S, Cellai I, Luciani P, et al. Rosiglitazone stimulates adipogenesis and decreases osteoblastogenesis in human mesenchymal stem cells. J Endocrinol Invest. 2007;30:RC26–RC30.
18. Mudaliar S, Polidori D, Zambrowicz B, et al. Sodium-glucose cotransporter inhibitors:effects on renal and intestinal glucose transport:from bench to bedside. Diabetes Care. 2015;38:2344–2353.
19. Solomon DH, Mogun H, Garneau K, et al. Risk of fractures in older adults using antihypertensive medications. J Bone Miner Res. 2011;26:1561–1567.
20. Taylor SI, Blau JE, Rother KI. Possible adverse effects of SGLT2 inhibitors on bone. Lancet Diabetes Endocrinol. 2015;3:8–10.
21. Rosenthal N, Meininger G, Ways K, et al. Canagliflozin:a sodium glucose co-transporter 2 inhibitor for the treatment of type 2 diabetes mellitus. Ann N Y Acad Sci. 2015;1358:28–43.
22. Usiskin K, Kline I, Fung A, et al. Safety and tolerability of canagliflozin in patients with type 2 diabetes:pooled analysis of phase 3 study results. Postgrad Med. 2014;126:16–34.
23. Nicolle LE, Capuano G, Fung A, et al. Urinary tract infection in randomized phase III studies of canagliflozin, a sodium glucose co-transporter 2 inhibitor. Postgrad Med. 2014;126:7–17.
24. Nyirjesy P, Sobel JD, Fung A, et al. Genital mycotic infections with canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitus:a pooled analysis of clinical studies. Curr Med Res Opin. 2014;30:1109–1119.
25. Weir M, Januszewicz A, Gilbert R, et al. Effect of canagliflozin on blood pressure and adverse events related to osmotic diuresis and reduced intravascular volume in patients with type 2 diabetes mellitus. J Clin Hypertens (Greenwich). 2014;16:875–882.
26. Kissner T, Doyle N, Samadfam R, et al. Bone as a target tissue in the toxicological assessment of anti-diabetes drug class of SGLT1 inhibitors. Toxicologist. 2010. Presented at:49th Annual Meeting of the Society of Toxicology; March 7–11, 2010; Salt Lake City, Utah. Abstract 117.
27. Tirmenstein M, Dorr TE, Janovitz EB, et al. Nonclinical toxicology assessments support the chronic safety of dapagliflozin, a first-in-class sodium-glucose cotransporter 2 inhibitor. Int J Toxicol. 2013;32:336–350.
28. Ways K, Johnson MD, Mamidi RNVS, et al. Successful integration of non-clinical and clinical findings in interpreting the clinical relevance of rodent neoplasia with a new chemical entity. Toxicol Pathol J. 2015;43:48–56.
29. Mamidi RNVS, Proctor J, De Jonghe S, et al. Carbohydrate malabsorption mechanism for tumor formation in rats treated with the SGLT2 inhibitor canagliflozin. Chem Biol Interact. 2014;221:109–118.
30. De Jonghe S, Proctor J, Vinken P, et al. Carcinogenicity in rats of the antidiabetic SGLT2 inhibitor canagliflozin. Chem Biol Interact. 2014;224:1–12.
31. FDA Briefing Document. NDA 202293 Dapagliflozin tablets, 5 and 10 mg. Endocrinologic and Metabolic Drugs Advisory Committee meeting [Internet]. 2011 Jul 19. Food and Drug Administration; Available from:http://www.fda.gov/downloads/AdvisoryCommittee/UCM262994.pdf.
32. European public assessment report (EPAR) for Jardiance (Empagliflozin). EMEA/H/C/002677/0000. 2014 Mar 20 [Internet]. European Medicines Agency (EMA), Committee for Medicinal Products for Human Use (CHMP); Available from:http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002677/WC500168594.pdf.
33. Kellett GL. Alternative perspective on intestinal calcium absorption:proposed complementary actions of Ca(v)1.3 and TRPV6. Nutr Rev. 2011;69:347–370.
34. Klinger S, Schroder B, Gemmer A, et al. Gastrointestinal transport of calcium and glucose in lactating ewes. Physiol Rep. 2016;4:e12817.
35. Weir MR, Kline I, Xie J, et al. Effect of canagliflozin on serum electrolytes in patients with type 2 diabetes in relation to estimated glomerular filtration rate (eGFR). Curr Med Res Opin. 2014;30:1759–1768.
36. Rosenstock J, Aggarwal N, Polidori D, et al. Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes. Diabetes Care. 2012;35:1232–1238.
37. Sha S, Devineni D, Ghosh A, et al. Pharmacodynamic effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, from a randomized study in patients with type 2 diabetes. PLoS One. 2014;9:e110069.
38. Bode B, Stenlöf K, Sullivan D, et al. Efficacy and safety of canagliflozin treatment in older subjects with type 2 diabetes mellitus:a randomized trial. Hosp Pract. 2013;41:72–84.
39. Yale JF, Bakris G, Cariou B, et al. Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease. Diabetes Obes Metab. 2013;15:463–473.
40. Yale JF, Bakris G, Cariou B, et al. Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease. Diabetes Obes Metab. 2014;16:1016–1027.
41. Inagaki N, Kondo K, Yoshinari T, et al. Efficacy and safety of canagliflozin in Japanese patients with type 2 diabetes:a randomized, double-blind, placebo-controlled, 12-week study. Diabetes Obes Metab. 2013;15:1136–1145.
42. Iijima H, Kifuji T, Maruyama N, et al. Pharmacokinetics, pharmacodynamics, and safety of canagliflozin in Japanese patients with type 2 diabetes mellitus. Adv Ther. 2015;32:768–782.
43. Alba M, Xie J, Fung A, et al. The effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on mineral metabolism and bone in patients with type 2 diabetes mellitus. Curr Med Res Opin. 2016;32:1375–1385.
44. Devineni D, Vaccaro N, Polidori D, et al. Effects of hydrochlorothiazide on the pharmacokinetics, pharmacodynamics, and tolerability of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in healthy participants. Clin Ther. 2014;36:698–710.
45. Peacock M. Calcium metabolism in health and disease. Clin J Am Soc Nephrol. 2010;5(Suppl 1):S23–S30.
46. Morgan JL, Skulan JL, Gordon GW, et al. Rapidly assessing changes in bone mineral balance using natural stable calcium isotopes. Proc Natl Acad Sci U S A. 2012;109:9989–9994.
47. Rubin MR, Patsch JM. Assessment of bone turnover and bone quality in type 2 diabetic bone disease:current concepts and future directions. Bone Res. 2016;4:16001.
48. Christenson RH. Biochemical markers of bone metabolism:an overview. Clin Biochem. 1997;30:573–593.
49. Wheater G, Elshahaly M, Tuck SP, et al. The clinical utility of bone marker measurements in osteoporosis. J Transl Med. 2013;11:201.
50. Rubin MR. Bone cells and bone turnover in diabetes mellitus. Curr Osteoporos Rep. 2015;13:186–191.
51. Starup-Linde J, Vestergaard P. Biochemical bone turnover markers in diabetes mellitus–A systematic review. Bone. 2016;82:69–78.
52. Kanazawa I. Osteocalcin as a hormone regulating glucose metabolism. World J Diabetes. 2015;6:1345–1354.
53. Hlaing TT, Compston JE. Biochemical markers of bone turnover–uses and limitations. Ann Clin Biochem. 2014;51:189–202.
54. Bilezikian JP, Watts NB, Usiskin K, et al. Evaluation of bone mineral density and bone biomarkers in patients with type 2 diabetes mellitus treated with canagliflozin, a sodium glucose co-transporter 2 inhibitor. J Clin Endocrinol Metab. 2016;101:44–51.
55. Bays HE, Weinstein R, Law G, et al. Canagliflozin:effects in overweight and obese subjects without diabetes mellitus. Obesity (Silver Spring). 2014;22:1042–1049.
56. Hyldstrup L, Andersen T, McNair P, et al. Bone metabolism in obesity:changes related to severe overweight and dietary weight reduction. Acta Endocrinol (Copenh). 1993;129:393–398.
57. Bleicher K, Cumming RG, Naganathan V, et al. The role of fat and lean mass in bone loss in older men:findings from the CHAMP study. Bone. 2011;49:1299–1305.
58. Schwartz AV, Johnson KC, Kahn SE, et al. Effect of 1 year of an intentional weight loss intervention on bone mineral density in type 2 diabetes:results from the Look AHEAD randomized trial. J Bone Miner Res. 2012;27:619–627.
59. Hinton PS, Rector RS, Linden MA, et al. Weight-loss-associated changes in bone mineral density and bone turnover after partial weight regain with or without aerobic exercise in obese women. Eur J Clin Nutr. 2012;66:606–612.
60. Zibellini J, Seimon RV, Lee CM, et al. Does diet-induced weight loss lead to bone loss in overweight or obese adults? A systematic review and meta-analysis of clinical trials. J Bone Miner Res. 2015;30:2168–2178.
61. Villareal DT, Fontana L, Das SK, et al. Effect of two-year caloric restriction on bone metabolism and bone mineral density in non-obese younger adults:a randomized clinical trial. J Bone Miner Res. 2016;31:40–51.
62. Yu EW, Wewalka M, Ding SA, et al. Effects of gastric bypass and gastric banding on bone remodeling in obese patients with type 2 diabetes. J Clin Endocrinol Metab. 2016;101:714–722.
63. Bolinder J, Ljunggren O, Johansson L, et al. Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin. Diabetes Obes Metab. 2014;16:159–169.
64. Melton LJ, III, Khosla S, Achenbach SJ, et al. Effects of body size and skeletal site on the estimated prevalence of osteoporosis in women and men. Osteoporos Int. 2000;11:977–983.
65. Burger H, Van Daele PL, Algra D, et al. The association between age and bone mineral density in men and women aged 55 years and over:the Rotterdam Study. Bone Miner. 1994;25:1–13.
66. Bode B, Stenlöf K, Harris S, et al. Long-term efficacy and safety of canagliflozin over 104 weeks in patients aged 55-80 years with type 2 diabetes. Diabetes Obes Metab. 2015;17:294–303.
67. Villareal DT, Fontana L, Weiss EP, et al. Bone mineral density response to caloric restriction-induced weight loss or exercise-induced weight loss:a randomized controlled trial. Arch Intern Med. 2006;166:2502–2510.
68. Jensen LB, Kollerup G, Quaade F, et al. Bone minerals changes in obese women during a moderate weight loss with and without calcium supplementation. J Bone Miner Res. 2001;16:141–147.
69. Fleischer J, Stein EM, Bessler M, et al. The decline in hip bone density after gastric bypass surgery is associated with extent of weight loss. J Clin Endocrinol Metab. 2008;93:3735–3740.
70. Watts NB, Bilezikian JP, Usiskin K, et al. Effects of canagliflozin on fracture risk in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab. 2016;101:157–166.
71. INVOKANA® (canagliflozin) tablets, for oral use [package insert]. Titusville, NJ:Janssen Pharmaceuticals; 2016.
72. Rodbard HW, Seufert J, Aggarwal N, et al. Efficacy and safety of titrated canagliflozin in patients with type 2 diabetes mellitus inadequately controlled on metformin and sitagliptin. Diabetes Obes Metab. 2016;18:812–819.
73. Zysset PK, Dall’ara E, Varga P, et al. Finite element analysis for prediction of bone strength. Bonekey Rep. 2013;2:386.
74. Garnero P, Sornay-Rendu E, Claustrat B, et al. Biochemical markers of bone turnover, endogenous hormones and the risk of fractures in postmenopausal women:the OFELY study. J Bone Miner Res. 2000;15:1526–1536.
75. Butt DA, Mamdani M, Austin PC, et al. The risk of hip fracture after initiating antihypertensive drugs in the elderly. Arch Intern Med. 2012;172:1739–1744.
76. Kelsey JL, Samelson EJ. Variation in risk factors for fractures at different sites. Curr Osteoporos Rep. 2009;7:127–133.
77. Diez-Perez A, Gonzalez-Macias J, Marin F, et al. Prediction of absolute risk of non-spinal fractures using clinical risk factors and heel quantitative ultrasound. Osteoporos Int. 2007;18:629–639.
78. Luetters CM, Keegan TH, Sidney S, et al. Risk factors for foot fracture among individuals aged 45 years and older. Osteoporos Int. 2004;15:957–963.
79. Gregg EW, Beckles GL, Williamson DF, et al. Diabetes and physical disability among older U.S. adults. Diabetes Care. 2000;23:1272–1277.
80. Wilding JP, Charpentier G, Hollander P, et al. Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea:a randomised trial. Int J Clin Pract. 2013;67:1267–1282.
81. Schernthaner G, Gross JL, Rosenstock J, et al. Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea:a 52-week, randomized trial. Diabetes Care. 2013;36:2508–2515.
82. Neal B, Perkovic V, de Zeeuw D, et al. Efficacy and safety of canagliflozin, an inhibitor of sodium glucose co-transporter 2, when used in conjunction with insulin therapy in patients with type 2 diabetes. Diabetes Care. 2015;38:403–411.
83. Fuller GF. Falls in the elderly. Am Fam Physician. 2000;61:2159-2168-2173-2174.
84. Tan MP, Kenny RA. Cardiovascular assessment of falls in older people. Clin Interv Aging. 2006;1:57–66.
85. Butt DA, Mamdani M, Austin PC, et al. The risk of falls on initiation of antihypertensive drugs in the elderly. Osteoporos Int. 2013;24:2649–2657.
86. Schwartz AV, Sellmeyer DE, Ensrud KE, et al. Older women with diabetes have an increased risk of fracture:a prospective study. J Clin Endocrinol Metab. 2001;86:32–38.
87. Lipscombe LL, Jamal SA, Booth GL, et al. The risk of hip fractures in older individuals with diabetes:a population-based study. Diabetes Care. 2007;30:835–841.
88. FARXIGA® (dapagliflozin) tablets, for oral use [package insert]. Princeton, NJ:Bristol-Myers Squibb Company; 2016.
89. JARDIANCE® (empagliflozin) tablets, for oral use [package insert]. Ridgefield, CT:Boehringer Ingelheim Pharmaceuticals, Inc.; 2016.
90. Egger A, Kraenzlin ME, Meier C. Effects of incretin-based therapies and SGLT2 inhibitors on skeletal health. Curr Osteoporos Rep. 2016;14:345–350.
91. Kohan DE, Fioretto P, Tang W, et al. Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control. Kidney Int. 2014;85:962–971.
92. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117–2128.
93. FDA Briefing Document:Endocrine and Metabolic Drug Advisory Committee meeting, 2016 Jun 28 [Internet]. Food and Drug Administration; Available from:http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM508422.pdf.
94. Endocrinologic and Metabolic Drugs Advisory Committee Briefing Document:EMPA-REG OUTCOME® Trial NDA 204629/NDA 206111, Jardiance® (empagliflozin)/Synjardy® (empagliflozin/metformin) [Internet]. Boehringer Ingelheim; Available from:http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM508423.pdf.
95. Tang HL, Li DD, Zhang JJ, et al. Lack of evidence for a harmful effect of sodium-glucose cotransporter 2 (SGLT2) inhibitors on fracture risk among type 2 diabetes patients:a network and cumulative meta-analysis of randomized controlled trials. Diabetes Obes Metab. 2016. DOI:10.1111/dom.12742. [Epub ahead of print].
96. Cosman F, de Beur SJ, LeBoff MS, et al. Clinician’s guide to prevention and treatment of osteoporosis. Osteoporos Int. 2014;25:2359–2381.